According to Prelude Therapeutics's latest financial reports the company's current EPS (TTM) is -1,98ย โฌ. In 2022 the company made an earnings per share (EPS) of -2,23ย โฌ a decrease over its 2021 EPS that were of -2,21ย โฌ.